Ligand Pharmaceuticals (LGND) Amortization - Intangibles (2015 - 2026)

Ligand Pharmaceuticals' Amortization - Intangibles history runs 12 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• In Q1 2026, Amortization - Intangibles fell 1.94% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $32.5 million (down 1.61% YoY), while the FY2025 annual figure was $32.7 million, down 0.91% from the prior year.
• Amortization - Intangibles came in at $8.1 million for Q1 2026 at Ligand Pharmaceuticals, roughly flat from $8.1 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $8.6 million in Q1 2022 to a low of $8.1 million in Q4 2025.
• A 5-year average of $8.3 million and a median of $8.3 million in 2024 frame the typical range for Amortization - Intangibles.
• On a YoY basis, Amortization - Intangibles climbed as much as 813.85% in 2022 and fell as far as 27.56% in 2022.
• Ligand Pharmaceuticals' Amortization - Intangibles stood at $8.5 million in 2022, then retreated by 1.93% to $8.3 million in 2023, then declined by 0.47% to $8.3 million in 2024, then fell by 2.54% to $8.1 million in 2025, then climbed by 0.11% to $8.1 million in 2026.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $8.1 million, $8.1 million, and $8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison